Oncology and Hematology - Global Oncology Academy

241-256 of 651

From Infusion to Injection: Can Subcutaneous Delivery Match Intravenous Standards in Oncology?
From Infusion to Injection: Can Subcutaneous Delivery Match Intravenous Standards in Oncology?
Project Oncology®
From Infusion to Injection: Can Subcutaneous Delivery Match Intravenous Standards in Oncology?
Optimizing Colorectal Cancer Screening: A Stress Test of Current Guidelines
Optimizing Colorectal Cancer Screening: A Stress Test of Current Guidelines
Clinician's Roundtable
Optimizing Colorectal Cancer Screening: A Stress Test of Current Guidelines
Pedro Nascimento de Lima, PhD
- Pedro Nascimento de Lima, PhD
Are Subcutaneous Immunotherapies Expanding Access and Efficiency in Cancer Care?
Are Subcutaneous Immunotherapies Expanding Access and Efficiency in Cancer Care?
Project Oncology®
Are Subcutaneous Immunotherapies Expanding Access and Efficiency in Cancer Care?
Ryan Quigley
- Ryan Quigley
Supplement Use for Colorectal Cancer Prevention: Insights from NCCN Guidelines
Supplement Use for Colorectal Cancer Prevention: Insights from NCCN Guidelines
Clinician's Roundtable
Supplement Use for Colorectal Cancer Prevention: Insights from NCCN Guidelines
Reid Ness, MD
- Reid Ness, MD
From Infusion Chair to Clinic Visit: How Subcutaneous Nivolumab May Simplify RCC Care
From Infusion Chair to Clinic Visit: How Subcutaneous Nivolumab May Simplify RCC Care
Project Oncology®
From Infusion Chair to Clinic Visit: How Subcutaneous Nivolumab May Simplify RCC Care
Redefining First-Line Treatment in Endometrial Cancer: The Role of Immunotherapy
Redefining First-Line Treatment in Endometrial Cancer: The Role of Immunotherapy
Project Oncology®
Redefining First-Line Treatment in Endometrial Cancer: The Role of Immunotherapy
Brian Slomovitz, MD
- Brian Slomovitz, MD
Subcutaneous Pembrolizumab in mNSCLC: A Potential Shift in the Delivery Landscape
Subcutaneous Pembrolizumab in mNSCLC: A Potential Shift in the Delivery Landscape
Project Oncology®
Subcutaneous Pembrolizumab in mNSCLC: A Potential Shift in the Delivery Landscape
Advancing Endometrial Cancer Care: ADCs and Biomarker-Based Therapies
Advancing Endometrial Cancer Care: ADCs and Biomarker-Based Therapies
Project Oncology®
Advancing Endometrial Cancer Care: ADCs and Biomarker-Based Therapies
Brian Slomovitz, MD
- Brian Slomovitz, MD
Putting Patients First: Personalized Care in Metastatic Breast Cancer
Putting Patients First: Personalized Care in Metastatic Breast Cancer
On the Frontlines of Metastatic Breast Cancer
Putting Patients First: Personalized Care in Metastatic Breast Cancer
Ashley Baker, MSN, PMHNP; Giancarlo Moscol, M.D.
- Ashley Baker, MSN, PMHNP
- Giancarlo Moscol, M.D.
Disaster-Proofing Colorectal Cancer Screening: What We Learned from COVID-19
Disaster-Proofing Colorectal Cancer Screening: What We Learned from COVID-19
Clinician's Roundtable
Disaster-Proofing Colorectal Cancer Screening: What We Learned from COVID-19
Charles Turck, PharmD, BCPS, BCCCP; Gloria Coronado, PhD
- Charles Turck, PharmD, BCPS, BCCCP
- Gloria Coronado, PhD
Emerging and Practice Changing Data in Immunotherapy Strategies for Melanoma
Emerging and Practice Changing Data in Immunotherapy Strategies for Melanoma
MinuteCE®
Emerging and Practice Changing Data in Immunotherapy Strategies for Melanoma
Sapna Patel, MD; John M. Kirkwood, MD
1.00 program credit
- Sapna Patel, MD
- John M. Kirkwood, MD
1.00 program credit
Data Driving Preferred Guideline Recommendations in First-Line Therapy for Metastatic Melanoma
Data Driving Preferred Guideline Recommendations in First-Line Therapy for Metastatic Melanoma
MinuteCE®
Data Driving Preferred Guideline Recommendations in First-Line Therapy for Metastatic Melanoma
Paolo A. Ascierto, MD; Hussein Tawbi, MD, PhD
1.00 program credit
- Paolo A. Ascierto, MD
- Hussein Tawbi, MD, PhD
1.00 program credit
Finding the Optimal Treatment for EGFR-mutated Metastatic NSCLC
Finding the Optimal Treatment for EGFR-mutated Metastatic NSCLC
MinuteCE®
Finding the Optimal Treatment for EGFR-mutated Metastatic NSCLC
Stephen Liu, MD; Joshua K. Sabari, MD
1.25 program credits
- Stephen Liu, MD
- Joshua K. Sabari, MD
- Susan Scott, MD
1.25 program credits
Updates in Limited-Stage Small Cell Lung Cancer (LS-SCLC)
Updates in Limited-Stage Small Cell Lung Cancer (LS-SCLC)
MinuteCE®
Updates in Limited-Stage Small Cell Lung Cancer (LS-SCLC)
Stephen Liu, MD; Joshua K. Sabari, MD
1.25 program credits
- Stephen Liu, MD
- Joshua K. Sabari, MD
- Susan Scott, MD
1.25 program credits
DESTINY-Breast04 Findings: T-DXd and Quality of Life in HER2-Low Metastatic Breast Cancer
DESTINY-Breast04 Findings: T-DXd and Quality of Life in HER2-Low Metastatic Breast Cancer
On the Frontlines of Metastatic Breast Cancer
DESTINY-Breast04 Findings: T-DXd and Quality of Life in HER2-Low Metastatic Breast Cancer
Marlene Mimi Maeusli, PhD.
- Marlene Mimi Maeusli, PhD.
Insights From Global Key Opinion Leaders on Regional Regulatory and Guideline Nuances to Optimize Melanoma Management
Insights From Global Key Opinion Leaders on Regional Regulatory and Guideline Nuances to Optimize Melanoma Management
MinuteCE®
Insights From Global Key Opinion Leaders on Regional Regulatory and Guideline Nuances to Optimize Melanoma Management
Hussein Tawbi, MD, PhD; Paolo A. Ascierto, MD
1.00 program credit
- Hussein Tawbi, MD, PhD
- Paolo A. Ascierto, MD
1.00 program credit

16/11